Concord Biotech (BOM:543960) Margin of Safety % (DCF Earnings Based): N/A (As of Jul. 01, 2026)


BOM:543960 Concord Biotech Ltd BOM:543960
68 GF Score
Price ₹1,277.85
GF Value ₹1,640.84
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Concord Biotech Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Concord Biotech's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

BOM:543960 vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Concord Biotech's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Concord Biotech Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Concord Biotech's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Concord Biotech's Margin of Safety % (DCF Earnings Based) falls into.


BOM:543960
68GF Score
Concord Biotech Ltd BOM:543960
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Concord Biotech (BOM:543960) Overvalued in 2026?

Based on GuruFocus' analysis, Concord Biotech stock appears to be undervalued. The current stock price of ₹1,277.85 is trading 22.1% below its estimated GF Value™ of ₹1,640.84. GuruFocus considers Concord Biotech to be Modestly Undervalued.

Key valuation signals for BOM:543960:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: ₹1,640.84 vs. price of ₹1,277.85 (22.1% below fair value)
  • GF Score™: 68/100 with 3 warning signs

No single metric tells the full story. See the BOM:543960 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Concord Biotech Business Description

Other Exchanges CONCORDBIO:India
Address Iscon Cross Road, S.G. Highway, B-1601-1602, B-Wing, Mondeal Heights, Ahmedabad, GJ, IND, 380015
Concord Biotech Ltd is a research and development-driven biopharma company that manufactures Active Pharmaceutical Ingredients (API) through fermentation and semi-synthetic process and finished formulations. It is mainly engaged in the business of manufacturing and trading in pharmaceutical products. Geographically Company operates in two segments within India and outside India, having majority revenue from India.
68GF Score

Get the complete analysis for BOM:543960

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,277.85
Price
₹1,640.84
GF Value